Wealth Enhancement Advisory Services
PCRX icon

Wealth Enhancement Advisory Services’s Pacira BioSciences PCRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311K Buy
12,221
+833
+7% +$19.7K ﹤0.01% 3170
2026
Q1 		$259K Buy
11,388
+1,933
+20% +$43K ﹤0.01% 2920
2025
Q4 		$239K Buy
9,455
+43
+0.5% +$1.02K ﹤0.01% 3123
2025
Q3 		$222K Buy
9,412
+153
+2% +$3.76K ﹤0.01% 3037
2025
Q2 		$215K Buy
+9,259
New +$233K ﹤0.01% 2932

Other funds holding PCRX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Wealth Enhancement Advisory Services's PCRX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Pacira BioSciences (PCRX) stake by 7.3% in Q2 2026, buying an estimated $19.7K and bringing the position to 12,221 shares worth $311K. The position accounts for ﹤0.01% of the portfolio, ranked #3170.

Wealth Enhancement Advisory Services first reported a position in PCRX in Q2 2025 and has held it in 5 quarters since. 26 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 12,221 shares of Pacira BioSciences worth $311K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 833 Pacira BioSciences shares in Q2 2026, an estimated $19.7K.
  • Pacira BioSciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3170 holding.
  • Wealth Enhancement Advisory Services first reported a position in Pacira BioSciences in Q2 2025 and has held it in 5 quarters since.
  • 26 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.